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Abstract: 2-Alkyl-1-alkanols offer an example whereby the category approach to read-across 14 
can be used to predict repeated-dose toxicity for a variety of derivatives. Specifically, the 15 
NOAELs of 125 mg/kg bw/d for 2-ethyl-1-hexanol and 2-propyl-1-heptanol, the source 16 
substances, can be read across with confidence to untested 2-alkyl-1-alkanols in the C5 to C13 17 
category based on a LOAEL of low systemic toxicity. These branched alcohols, while non-18 
reactive and exhibiting unspecific, reversible simple anaesthesia or nonpolar narcosis mode of 19 
toxic action, have metabolic pathways that have significance to repeated-dose toxic potency. In 20 
this case study, the chemical category is limited to the readily bioavailable analogues. The 21 
read-across premise includes rapid absorption via the gastrointestinal tract, distribution in the 22 
circulatory system and first-pass metabolism in the liver via Phase 2 glucuronidation prior to 23 
urinary elimination. 2-Ethyl-1-hexanol and 2-propyl-1-heptanol, the source substances, have 24 
high quality 90-day oral repeated-dose toxicity studies (OECD TG 408) that exhibit qualitative 25 
and quantitative consistency. Findings include only mild changes consistent with low-grade 26 
effects including decreased body weight and slightly increased liver weight, which in some 27 
cases is accompanied by clinical chemical and haematological changes but generally without 28 
concurrent histopathological effects at the LOAEL. These findings are supported by results 29 
from the TG 408 assessment of a semi-defined mixture of isotridecanols. Chemical similarity 30 
between the analogues is readily defined and data uncertainty associated with toxicokinetic and 31 
toxicodynamics similarities are low. Uncertainty associated with mechanistic relevance and 32 
completeness of the read-across is reduced by the concordance of in vivo and in vitro results, as 33 
well as high throughput and in silico methods data. As shown in detail, the 90-day rat oral 34 
repeated-dose NOAEL values for the two source substances can be read across to fill the data 35 
gaps of the untested analogues in this category with uncertainty deemed equivalent to results 36 
from a TG 408 assessment. 37 
Keywords: read-across, n-alkanols, repeated-dose toxicity, No Observed Adverse Effect Level 38 
(NOAEL), Lowest Observed Adverse Effect Level (LOAEL), weight-of-evidence (WoE), 39 
uncertainty 40 
 41 
42 
Highlights:  43 
• The category is limited to readily bioavailable 2-alkyl-1-akanols of intermediate size 44 
(C5 to C13) 45 
• 2-Alkyl-1-akanols are toxicants acting via a simple narcosis mechanism 46 
• Toxicokinetically and toxicodynamically, the 2-alkyl-1-akanols are highly similar 47 
• 2-ethyl-hexanol and 2-propyl-1-heptanol can be read across to other analogues with 48 
acceptable uncertainty 49 
50 
1 Introduction 51 
1.1 Read-across 52 
In a toxicity based read-across, it is imperative to demonstrate that all target substances exhibit 53 
similar chemical, toxicokinetic and toxicodynamic properties so experimentally-derived 54 
information and data from the source substances may be read across to fill the data gap for the 55 
target substances [1, 2]. This type of data gap filling is particularly useful for cosmetic 56 
ingredients where in vivo testing in Europe is prohibited by legislation [3]. 57 
While read-across has been used by industry and regulators for decades, recent advances, 58 
especially in non-animal test methods, has resulted in read-across today being held to a higher 59 
standard [4, 5].  60 
The read-across strategy employed here focuses on assessing the similarity between target(s) 61 
and source substance(s) and the uncertainties in the read-across process and ultimate 62 
prediction, two fundamentals of a read-across estimation [6]. Briefly, the justification of read-63 
across prediction needs to be robust, reliable and easily explicable. The crucial principles of 64 
similarity are clearly documented and supported by scientific literature and data. Sources of 65 
uncertainty, the uncertainty associated with the justification of similarity, and the uncertainty 66 
associated with the particular application are identified and accommodated. 67 
As such, the current study describes a case that illustrates a number of issues associated with a 68 
category approach for the scenario in which metabolism, while straight forward, is important in 69 
determining molecular similarity. Thus, establishing toxicodynamic, as well as toxicokinetic 70 
similarity, is critical to reducing uncertainties associated with the repeated-dose toxicity 71 
predictions. 72 
The present study builds on an early finding [2]. Specifically, an initial evaluation of a wide 73 
variety of saturated alcohols revealed that, based on consideration of a common metabolic 74 
pathway the saturated alcohols need to be sub-categorised prior to making read-across 75 
predictions. 76 
1.2 C5-C13 2-alkyl-1-alkanols: Overview of Existing Knowledge 77 
As previously noted [2], intermediate chain-length primary alkanols are considered non-polar 78 
narcotics which act mechanistically in a manner similar to depressant anaesthetics. Perfused rat 79 
liver toxicity data from Strubelt et al. [7] for the C5 primary alkanol exposure of 65.1 mmol/l 80 
for 2 hours suggests that 2-alkyl-1-alkanols may not be in the same read-across category as 81 
other primary alkanols (Table 1). These data support the premise that in vitro toxicity (e.g., O2 82 
consumption and ATP production) of 2-alkyl-1-alkanols is due, in large part, to loss of 83 
membrane integrity, as indicated by cytosolic enzyme (LDH) leakage. While it is likely that 84 
enzyme leakage is the result of alteration in membrane fluidity due to partitioning in the cell 85 
membrane, loss of membrane integrity as a result of soft electrophilic reactivity and indicated 86 
by a 50% reduction in free glutathione (GSH) is not likely. 87 
Table 1. In vitro toxicity profiles for selected alkanols. 88 
Name log Kow O2 Consumption 
(µmol/g x min) 
ATP 
(µmol/g) 
LDH 
(U/l) 
GSH 
(µmol/g) 
Control  1.54 ± 0.07 1.25 ± 0.20 1109 ± 265 2.52 ± 0.29 
2-Methyl-1-butanol 1.30 0.30 ± 0.03 0.10 ± 0.01 20521±1087 1.33 ± 0.29 
3-Methyl-1-butanol 1.16 0.22 ± 0.07 0.27 ± 0.05 8680 ± 1216 2.27 ± 0.37 
1-Pentanol 1.40 0.06 ± 0.01 0.20 ± 0.03 28959 ± 4142 2.82 ± 0.36 
LDH – lactate dehydrogenase; ATP - adenosine triphosphate; GSH – reduced glutathione 89 
Due to bioavailability, and distribution and mechanistic considerations, the applicability 90 
domain for this case study is limited to 2-alkyl-1-alkanols with a carbon atom (C) chain length 91 
range of C5 to C13. Since long-chain derivatives are typically transported via carrier 92 
molecules, alcohols of C14 and greater are not included in this category. Since shorter-chain 93 
derivatives (e.g., isopropyl alcohol) have the potential to volatilise, they also are not included 94 
in this category. 95 
Among the 2-alkyl-1-alkanols, 2-ethyl-1-hexanol is the most widely studied [8, 9, 10, 11, 12]. 96 
Dermal penetration of intermediate size alkanols does not readily occur and absorption from 97 
inhalation is extremely limited [13]. Thus, the primary route of exposure, which is 98 
toxicologically relevant, is oral. Two-alkyl-1-alkanols within the range C5-C13 are expected to 99 
be readily absorbed by the gastrointestinal tract and distributed in the blood in solution [14]. 100 
Metabolism of 2-alkyl-1-alkanols, while highly efficient, involves processes that are more 101 
complex than n-alkanol metabolism. Experimental data reveals the major pathways of 102 
metabolism and fate of 2-alkyl-1-alkanols include: 1) conjugation of the alcohol group with 103 
glucuronic acid; 2) oxidation of the alcohol group; 3) side-chain oxidation yielding additional 104 
polar metabolites, which may be subsequently conjugated and be excreted or further oxidised, 105 
and 4) excretion of the unchanged parent compound. For example, in rabbits, the glucuronide 106 
of 2-ethyl-1-hexanoic acid was identified as the main metabolite (87%) after oral application of 107 
2-ethyl-1-hexanol [15, 16]. In contrast, in the same species, only about 9% of the administered 108 
dose of 2-methyl-1-butanol was found in the form of the glucuronides [15, 16]. 109 
Belsito et al. [14] reviewed the toxicity of branched chain saturated alcohols, including 110 
secondary ones. Patocka and Kuca [17] summarized the toxicity of C1 to C6 alkanols. The 111 
efficacy of alkanols to induce ataxia [18] and enzyme release from liver cells [19] has been 112 
interpreted as being due to the hydrophobic property of the alkanols. Based on rat and fish 113 
studies, 2-alkyl-1-alkanols, like other alkanols, act in a manner similar to depressant 114 
anaesthetics [20, 21]. Koleva et al. [22] reported multiple-regression type quantitative 115 
structure-toxicity relationships (QSARs) for oral log LD50-1 data for rodents and the 1-116 
octanol/water partition coefficient (log Kow). Comparison of measured toxicity data with 117 
predictions from baseline QSARs reveals that straight-chain and branched, saturated 118 
monohydric alcohols consistently behave as classic nonpolar narcotics. 119 
A cursory summary of the rodent oral acute and oral repeated-dose toxicity of intermediate size 120 
2-alkyl-1-akanols are presented in Table 2. In general, 2-alkyl-1-akanols acute oral toxicity 121 
(LD50) is very low ranging from ≈2000 to < 5000 mg/kg bw with an average value of ≈3500 122 
mg/kg bw. 123 
Table 2. Acute and repeated-dose oral toxicity of selected 2-alkyl-1-alkanols 124 
Alcohol Species Oral LD50 
(mg/kg)  
Reference 90-d Oral NOAEL 
(mg/kgbw/d) 
Reference 
2-Methyl-1-butanol Rat 4010 [23] Not determined  
2-Methyl-1-pentanol  Not determined  Not determined  
2-Ethyl-1-butanol Rat 1850 [24] Not determined  
2-Ethyl-1-pentanol Rat Not determined  Not determined  
2-Ethyl-1-hexanol Rat >3730 [25] 125 [26, 27] 
 Rat ≈2000 [27] Not determined  
 Mouse 2500 [28] 125 [26] 
2-Propyl-1-pentanol  Not determined  Not determined  
2-Methyl-1-octanol  Not determined  Not determined  
2-Ethyl-1-octanol  Not determined  Not determined  
2-Propyl-1-heptanol Rat 5400 [29] 150 [29] 
2-Methyl-1-undecanol  Not determined  Not determined  
2-Ethyl-1-decanol  Not determined  Not determined  
2-Propyl-1-decanol  Not determined  Not determined  
 125 
2-Alkyl-1-akanols are slightly toxic in oral repeated-dose testing; typically, the rodent, oral, 126 
90-day, repeated-dose No Observed Adverse Effect Level (NOAEL) in mg/kg bw/d is ≥ 125 127 
mg/kg bw/d (see Table 2). This value is characteristically based on clinical symptoms, 128 
haematological values outside the normal range, or whole body effects different from normal. 129 
However, if ingested in large enough quantities, alkanols may cause systemic damage to the 130 
liver, heart, kidneys, and/or nervous system. 131 
2 Method and Materials 132 
This evaluation of selected 2-alkyl-1-akanols follows the workflow of Schultz et al. [2]. It is in 133 
accord with the guidance proposed by Organization for Economic Co-Operation and 134 
Development (OECD) [30] and Schultz and co-workers [6]. In vivo data used in the assessment 135 
were taken from the literature, including ECHA REACH Registered Substances database [31]. 136 
Mechanistic relevance, as well as toxicokinetic and toxicodynamic similarity of the category 137 
analogues, was established using relevant non-animal data. 138 
2.1 Target and Source Substances 139 
In this case study, the analogues (listed in Table 3) include ten target and two source 140 
chemicals; the latter, those with repeated-dose data derived from a 90-day OECD TG 408 141 
assay, are noted in bold print. This list is not meant to be all inclusive, rather it represents 142 
existing industrial organic materials that are likely to be found in a governmental or industrial 143 
inventory (e.g., OECD High Production Volume Chemicals). Additional substance identifier 144 
information, such as chemical structures and molecular formulas are available in Table 1 of the 145 
supplemental information. 146 
Table 3. 2-Alkyl-1-alkanols considered part of the chemical category. The source chemicals 147 
are in bold.  148 
ID Name CAS Molecular formula 
1 2-Methyl-1-butanol 137-32-6 C5H12O 
2 2-Methyl-1-pentanol 105-30-6 C6H14O 
3 2-Ethyl-1-butanol 97-95-0 C6H14O 
4 2-Ethyl-1-pentanol 27522-11-8 C7H16O 
5 2-Ethyl-1-hexanol 104-76-7 C8H18O 
6 2-Propyl-1-pentanol 58175-57-8 C8H18O 
7 2-Methyl-1-octanol 818-81-5 C9H20O 
8 2-Ethyl-1-octanol 20592-10-3 C10H22O 
9 2-Propyl-1-heptanol 10042-59-8 C10H22O 
10 2-Methyl-1-undecanol 10522-26-6 C12H26O 
11 2-Ethyl-1-decanol 21078-65-9 C12H26O 
12 2-Propyl-1-decanol 60671-35-4 C13H28O 
 149 
2.2 Endpoint 150 
The NOAEL for the 90-day rat oral repeated-dose is the single endpoint for which this 151 
category approach is applied. The 90-day oral repeated-dose data for 2-ethyl-hexanol and 2-152 
propyl-1-heptanol are particularly well-suited for read-across; the NOAELs are based on 153 
experimental results from a 4-dose exposure scenario (0, <100, between 100 and 200 and > 154 
500 mg/kg bw/d) following a standard test guideline (OECD TG 408) where the LOAEL 155 
symptoms are reported. 156 
2.3 Hypothesis of the category 157 
The premise for this read-across case study is: 158 
• 2-Alkyl-1-akanols of intermediate chain length (i.e., C5 to C13) are direct-acting 159 
toxicants (i.e., metabolic activation and detoxification is not a major factor in toxicity) 160 
with a similar reversible mode of action (i.e., non-polar narcosis or simple anaesthesia). 161 
• The chemical category is based on simple structure similarities- C-atom chain length 162 
and 2-alkan-1-ol hydrocarbon scaffolding. 163 
• With C5 to C13 2-alkanol-1-ol derivatives, C-atom chain length affects most physico-164 
chemical properties with property values increasing with increasing chain length. 165 
However, this trend is not toxicologically significant and does not significantly affect 166 
bioavailability in sub-chronic oral exposure. 167 
• These 2-alkyl-1-akanols are rapidly and nearly completely absorbed from the gut and 168 
distributed in the blood in solution; first past metabolism leads to glucuronidation with 169 
subsequent elimination in the urine and/or oxidative metabolism in the liver resulting in 170 
a carboxylic acid, which subsequently undergoes mitochondrial β-oxidation, and/or 171 
resulting in additional polar metabolites which are glucuronidated prior to excretion in 172 
the urine. 173 
• Toxicodynamically, these 2-alkyl-1-akanols are highly similar. Briefly, in vivo they 174 
exhibit low systemic toxicity and in vitro they exhibit no chemical reactivity or 175 
receptor-mediated interactions. 176 
• Repeated-dose tested NOAEL data for 2-ethyl-hexanol and 2-propyl-1-heptanol can be 177 
read across to other category members listed in Table 3 with acceptable uncertainty. 178 
3. Results 179 
3.1. Read-across Justification 180 
3.1.1 Rodent repeated-dose toxicity for 2-ethyl-1-hexanol 181 
From a repeated-dose perspective, 2-ethyl-1-hexanol is well-studied. More specifically, in a 182 
90-day study similar in design to an OECD TG408, Fischer F344 rats were administered doses 183 
of 0, 25, 125, 250 or 500 mg 2-ethyl-1-hexanol/kg bw/d by gavage [32]. A NOAEL of 125 184 
mg/kg bw/d based on reduced body weight and body weight gain, changes in blood chemistry 185 
were reported. 186 
A second sub-chronic gavage study is reported by the same authors [33] in which Fischer rats 187 
were exposed to doses of 0, 25, 250 and 500 mg/kg bw/d. Relative weight changes are reported 188 
for kidney and liver, as well as a decrease of alanine aminotransferase at 250 mg/kg bw/d. 189 
Further weight changes occurred in brain, testes and stomach at highest dose, together with a 190 
slight decrease in body weight. Changes in clinical chemistry parameters were reported, 191 
including an increased activity of the enzyme palmitoyl coenzyme A activity (pCoA), decrease 192 
of cholesterol, total protein and albumin, as well as an increase in reticulocytes. Since no doses 193 
between 25 and 250 were tested, the NOAEL of this study is 25 mg/kg bw/d. 194 
In a chronic Fischer F344 rat study, 2-ethyl-1-hexanol was administered by gavage at doses of 195 
0, 50, 150 or 500 mg/kg bw/d, 5 days per week for 2 years [34]. Food consumption, body 196 
weights, and haematological parameters were examined at specific intervals during the study. 197 
At the end of the study, gross and histopathological examinations were conducted. No 198 
treatment-related adverse effects were observed at the 50 mg/kg bw/d dose level. At the 150 199 
mg/kg bw/d dose level, rats exhibited a body weight gain reduction of approximately 16% in 200 
males and 12% in females. An increase of brain and liver weight also is reported. However, no 201 
histopathological changes were observed at same or higher doses. In addition, the rats also 202 
displayed a slightly increased incidence of clinical signs, such as poor general condition and 203 
laboured breathing. We conclude that the NOAEL for this study is 150 mg/kg bw/d. 204 
Shorter-term repeated dose studies are also available for 2-ethyl-1-hexanol. In an 11-day study, 205 
Fischer 344 rats were exposed by gavage at doses of 0, 100, 330, 1000 and 1500 mg/kg bw/d 206 
[35]. From 330 mg/kg bw/d on, atrophy of the thymus was reported being most pronounced at 207 
1500 mg/kg bw/d. At 1000 mg/kg bw/d a decrease in reticulocytes and clinical chemistry 208 
parameters such as cholesterol, glucose and ALAT was reported, as well as a marked 209 
inflammation of the forestomach. At highest tested dose, additional adverse effects were 210 
reported, including focal hepatocellular necrosis, hepatocellular hypertrophy and several organ 211 
weight changes. Transient clinical signs were reported at 1000 and 1500 mg/kg bw/d, namely 212 
ataxia, lethargia and lateral and abdominal posturing. A NOAEL of 100 mg/kg bw/d was 213 
determined. 214 
A second short-term gavage study was done with Fischer rats exposed to doses of 0, 100, 320 215 
and 950 mg/kg bw/d for 28 days [36]. At the highest dose of 950 mg/kg bw/d body weight gain 216 
was reduced and kidney and liver weight and triglycerides were increased. At 320 mg/kg bw/d 217 
an induction of peroxisome proliferation was observed, as well as hepatic cyanide-insensitive 218 
palmitoyl coenzyme A activity (pCoA). At 100 mg/kg bw/d a reduction of neutral lipids in 219 
liver is reported; however, we do not consider this toxicologically relevant and, thus, we 220 
conclude the NOAEL for this study to be 100 mg/kg bw/d. 221 
In a 90-day study, B6C3F1 mice received doses of 0, 25, 125, 250 or 500 mg 2-ethyl-1-222 
hexanol/kg bw/d [26] and the 90-day oral NOEL was noted as 125 mg/kg bw/d. 223 
In another B6C3F1 mouse study, 2-ethyl-1-hexanol mice were administered by gavage at doses 224 
of 0, 50, 200 or 750 mg/kg bw/d, five days per week for 18 months [32]. Food consumption, 225 
body weights and haematological parameters were examined at specific intervals during the 226 
study. At the end of the study, gross and histopathological examinations were conducted. 227 
While no treatment-related adverse effects were observed in the mice receiving 50 or 200 mg 228 
2-ethyl-1-hexanol/kg bw/d, at the 750 mg/kg bw/d dose level, body weight gain reductions of 229 
approximately 26 and 24% in males and females, respectively. Further high dose effects 230 
consist of changes in haematology (lymphocytes, neutrophil increase after 12 months), weight 231 
changes of different organs (kidney, liver), and hyperplasia in the forestomach. We conclude 232 
the NOAEL for this study to be 200 mg/kg bw/d. 233 
3.1.2 Rodent repeated-dose toxicity for 2-propyl-1-heptanol 234 
In an OECD TG 408 test, oral 90-day repeated-dose assay, male and female Fischer 344 rats 235 
were exposed via gavage to 0, 30, 150 and 600 mg/kg bw/d of 2-propyl-1-heptanol [29]. 236 
Histopathological findings at 600 mg/kg bw/d include diffuse liver hypertrophy, likely the 237 
result of peroxisome proliferation, diffuse hypertrophy of follicular cells in the thyroid gland, 238 
and vacuolation of basophilic (thyrotropic) cells in the glandular part of the pituitary gland. 239 
Additionally, alterations based on clinical signs were observed at 600 mg/kg bw/d. 240 
Disregarding peroxisomal proliferation, the NOAEL for this study was 150 mg/kg bw/d. 241 
3.1.3 Other related rodent repeated-dose studies 242 
Isotridecanol (i.e., C13-rich mixture of iso-alcohols of C11-14, CAS No. 68526-86-3) was 243 
tested by gavage to Sprague–Dawley rats [14]. In a 90-day study, according to OECD TG 408 244 
with doses of 0, 100, 500, or 1000 mg/kg bw/d, the NOAEL of 100 mg/kg bw/d was reported 245 
[14]. 246 
While ECHA CHEM notes a reliable read-across from 3-methyl-1-butanol to 2-methyl-1-247 
butanol, the current study disregarded these data. This decision was based on the finding of 248 
Strubelt and co-workers. [7]. Data (see Table 1) for the C5 primary alkanols exposure 65.1 249 
mmol/l for 2 hours suggest that 2-methyl-1-butanol may not be in the same read-across 250 
category as 3-methyl-1-butanol or n-pentanol. 251 
In summary, two 2-alkyl-1-akanols (i.e., 2-ethyl-hexanol and, 2-propyl-1-heptanol) have high 252 
quality quantitative (e.g., OECD TG 408) 90-day oral exposure repeated-dose test data. These 253 
data exhibit qualitative and quantitative consistency between and within rodent species. 254 
Specifically, results of oral repeated-dose testing for these two source substances suggest mild 255 
changes consistent with low-grade effects, including decreased body weight, accompanied by 256 
clinical chemical and haematological changes but generally without concurrent 257 
histopathological effects. While it can be argued that these effects are not adverse, we still 258 
considered them in determining the NOAEL. The 90-day oral exposure repeated-dose NOAEL 259 
values ≥ 125 mg/kg bw/d are based on experimental results from a four dose exposure 260 
scenario, typically 0, <100, between 100 and 200, >200 and ≥500. While there is not repeated-261 
dose toxicity data for 2-methyl derivatives, they are included in the category. 262 
3.2. Applicability domain 263 
As previously noted, the applicability domain for this case study is confined to branched 264 
primary alkanols of intermediate size, C5 to C13. Straight-chain derivatives, which exhibit a 265 
different toxicokinetic profile, are excluded from this chemical category. Briefly, metabolism 266 
of straight-chain saturated alcohols resulting in the corresponding carboxylic acid, which 267 
subsequently undergoes mitochondrial β-oxidation to CO2 with only minor amounts of Phase 2 268 
glucuronidation [2]. 269 
3.3. Purity/impurities 270 
A purity/impurity profile for the analogues listed in Table 3 is not reported. No effort was 271 
made to take into account impurities based on production. Since the category is structurally 272 
limited, the impurities are expected to be similar if not the same across the members and are 273 
not expected to significantly impact the toxicity profile of any analogue. 274 
3.4 Data matrices for assessing similarity 275 
As earlier noted, in order for a read-across prediction to be accepted, there is the requirement to 276 
establish similarity between the source and target substance; toxicokinetic similarity, especially 277 
for metabolism, and toxicodynamic similarity, especially in regard to mechanistic plausibility 278 
is required for repeated dose-toxicity endpoints [1, 2]. 279 
3.4.1 Structural similarity 280 
As demonstrated in Tables 1 and 3 of the supplemental information, all the branched alkanols 281 
included in the category are structurally highly similar. Specifically, they: 1) belong to a 282 
common chemical class, aliphatic alcohols and the subclasses primary alkanols and 2-alkyl-1-283 
alkanols, and 2) possess a similar molecular scaffolding, a C-atom backbone with alkyl 284 
branching in the 2-position. Structurally, the main variations are the length of the backbone, 285 
C5-C11 and the length of the alkyl-substituent, C1-C3. 286 
3.4.2 Chemical property similarity 287 
As demonstrated in Table 2 of the supplemental information, all the primary alkanols included 288 
in the category have a large portion of their physio-chemical properties determined 289 
experimentally. Properties, with the exception of density and pKa, tread in values related to C-290 
atom number within a scaffold. Specifically, all category members exhibit molecular weights 291 
from 88 to 200 g/mol. While hydrophobicity (log Kow) increases with number of C-atoms 292 
from >1.0 to <6.0, density and pKa are constant at 0.8 g/cm3 and 15. While vapour pressure 293 
and water solubility decrease with molecular size, melting point and boiling point increase with 294 
molecular size. 295 
3.4.3 Chemical constituent similarity 296 
As demonstrated in Table 3 of the supplemental information, all the branched primary alkanols 297 
included in the category have common constituents in the form of: 1) a single key substituent, 298 
OH, and 2) structural fragments, CH3, CH2 and CH. 299 
3.4.4 Toxicokinetic similarity 300 
As demonstrated in Table 4 of the supplemental information, while the analogues tested are 301 
limited, the toxicokinetic understanding of 2-position branched primary alkanol is fairly 302 
complete. Two-alkyl-1-alkanols are rapidly absorbed following oral administration [13] and 303 
are rapidly excreted [37]. Data for 2-ethyl-1-hexanol and to a lesser extent 2-methyl-1-butanol 304 
and 2-ethyl-1-butanol demonstrate that branched primary alcohols exhibit common metabolic 305 
pathways. These metabolic pathways include oxidation of the alcohol group and oxidation of 306 
the side chain at various positions, glucuronidation of the oxidation products and 307 
decarboxylation [37]. Glucuronidation increases with increased chain length of the alkanols 308 
[38]. 309 
Two adult male CD-strain rats (300 g) were gavaged with radiolabeled 2-ethyl-1-14C-hexanol 310 
(14C- labeled 2-ethyl-1-hexanol; 1 µCi; 8.8 µg) in cotton seed oil. Two others were given the 311 
same amount of 14C-EH and cotton seed oil but also were given 0.1 ml (0.64 mmol) of 312 
unlabeled 2-ethyl-1-hexanol. Following administration, rats were housed in metabolism cages 313 
and expired CO2, urine, and faeces were collected every hour for 28 hrs. Most (99.8%) of the 314 
orally administered radioactivity was accounted for by radioactivity in expired CO2, urine, 315 
faeces, an ethanol wash of the metabolism cage at the end of the experiment, heart, brain, liver, 316 
kidneys, and "residual carcass". Two-ethyl-1-hexanol was efficiently absorbed following oral 317 
administration and rapidly excreted in respired CO2 (6-7%), urine (80-82%), and faeces (8-318 
9%); elimination was essentially complete by 28 hrs [10, 27, 37]. 319 
Deisinger et al. [39, 40] examined the elimination of 14C-labeled 2-ethyl-1-hexanol in rats. 320 
After oral administration to rats, 69-75% of a dose of 500 mg 14C-labeled 2-ethyl-1-hexanol/kg 321 
bw was excreted in the urine within 96 hours; about 13 to 15% of the dose was excreted in the 322 
faeces and about the same amount was exhaled as 14C-labeled CO2. After intravenous 323 
administration to rats, about 74% of a dose of 1 mg 14C-labeled 2-ethyl-1-hexanol/kg bw was 324 
excreted in the urine within 96 hours. About 4% of the dose was excreted in the faeces and 325 
23% was exhaled. More than 50% of the dose was excreted within 8 hours and the terminal 326 
half-life was estimated to be 60 hours [39, 40]. 327 
Haggard et al. [41] examined the metabolic fate of 2-methyl-1-butanol in rats. Specifically, 328 
intraperitoneal injection in four equal doses of 250mg/kg bw at 15-min intervals resulted in a 329 
maximum blood concentration of 550 mg/l. Blood concentration decreased over the next nine 330 
hours. Of the total dose of 1000mg/kg bw, only 5.6% was excreted in air and 2% in the urine. 331 
The remainder was metabolised, first to the corresponding aldehyde and then to the acid [41]. 332 
After a single oral dose of 25 mmoles of 2-methyl-1-butanol to rabbits [15], 9.6% of the dose 333 
was excreted in the urine as glucuronides. Glucuronide excretion occurred within 24 hours, the 334 
urine did not contain aldehydes or ketones. Iwersen and Schmoldt [42] studied the alcohol 335 
dehydrogenase-independent metabolism of aliphatic alcohols (oxidation and glucuronidation). 336 
Briefly, male Sprague-Dawley rats were pre-treated with 10% ethanol in the drinking water for 337 
two weeks. Rats were sacrificed and microsomes were prepared for glucuronidation 338 
experiments and trials, as well as oxidation experiments with aliphatic alcohols. In vitro 339 
experiments have demonstrated additional oxidation of 2-methyl-1-butanol by rat liver 340 
microsomes via CYP P450 enzymes and glucuronidation. At very low ethanol concentrations 341 
(5-10 mmo/L) competitive inhibiting effect of ethanol on oxidation of 2-methyl-1-butanol was 342 
observed [42]. 343 
A rabbit was given 2.55g of 2-ethyl-1-butanol and the 24-hr urine was collected [16]. 2-Ethyl-344 
1-butanol was excreted mainly as glucuronides, along with a minor amount of methyl n-propyl 345 
ketone. 346 
3.4.5 Metabolic similarity 347 
As demonstrated in Table 5 of Annex I with data from in silico predictions, it is highly likely 348 
that all of the category members undergo successive oxidation to their corresponding aldehyde 349 
and carboxylic acid [43, 44]. 350 
Kamil et al. [15, 16] examined the metabolic fate of 2-methyl-1-hexanol in rats. Via acid 351 
extraction of urine, the major urinary metabolite of 2-ethyl-1-hexanol was revealed to be 2-352 
ethyl hexanoic acid. This metabolite may undertake partial ß-oxidation and decarboxylation to 353 
produce 14CO2 and 2- and 4-heptanone (in the urine). Other urinary metabolites identified in 354 
this study were 2-ethyl-5-hydroxyhexanoic acid, 2-ethyl-5-ketohexanoic acid, and 2-ethyl-1,6-355 
hexanedioic acid. Approximately 3% of the parent compound was excreted unchanged. 356 
Metabolic saturation was seen with 500 mg/kg body weight applied [15, 16].  357 
Typically, the presence of a side chain does not terminate the oxidation process of alkanols. 358 
However, in most cases, it alters it. The position and size of the alkyl substituent plays a role in 359 
metabolism with degradation to CO2 decreasing and glucuronidation increasing with branching 360 
and increasing chain length. 361 
Alkyl acids formed during metabolic transformation of branched alkanols have their own set of 362 
metabolic pathways. Acids with a methyl substituent located at an even-numbered carbon (e.g., 363 
2-methyl pentanoic acid or 4-methyl decanoic acid) are extensively metabolised to CO2 via ß-364 
oxidative cleavage in the fatty acid pathway. If the methyl group is located at the 3-position, ß-365 
oxidation is inhibited and omega (ω-) oxidation predominates, primarily leading to polar, 366 
acidic metabolites capable of being further oxidised or conjugated and excreted in the urine 367 
[44]. As chain length and lipophilicity increase, ω-oxidation competes with ß-oxidative 368 
cleavage. Methyl substituted acids (e.g., 3-methylnonanoic acid) are, to some extent, ω-369 
oxidized in animals to form diacids which can be detected in the urine [45]. 370 
Oxidation of these branched fatty acids is accomplished by alpha (α-) oxidation. α-Oxidation is 371 
a complex catabolic process. It initially involves hydroxylation of the α-C atom. Subsequently, 372 
the terminal carboxyl group is removed, and there is a concomitant conversion of the α-373 
hydroxyl group to a new terminal carboxyl group. Lastly, there is a linking of CoA to the 374 
terminal carboxyl group. This new branched, fatty acyl-CoA functions in the β-oxidation. In 375 
humans, α-oxidation is used in peroxisomes to break down dietary branched acids which 376 
cannot undergo β-oxidation due to β-methyl branching. 377 
Metabolism of methyl-substituted alcohols is determined primarily by the position of the 378 
methyl group(s) on the hydrocarbon-chain. Following successive oxidation to the 379 
corresponding carboxylic acids, the branched-chain acids are metabolised via ß-oxidation. 380 
With longer branched-chain derivatives, this is followed by cleavage to yield linear acid 381 
fragments which are typically completely metabolised to CO2. At high-dose levels, the longer 382 
branched-chain acids may go through omega-oxidation to yield diacids, which subsequently 383 
may undergo further oxidation and cleavage. 384 
The presence of an ethyl- or propyl-substitution at the α-position, such as in 2-ethyl-1-hexanol, 385 
inhibits ß-oxidation [46]. Detoxication pathways of ω- and ω-1 oxidation compete with ß-386 
oxidation of these sterically hindered substances; the parent alcohol or corresponding 387 
carboxylic acid undergoes a combination of reactions (e.g., ω- or ω-1 oxidation and functional 388 
group oxidation) leading to polar, acidic metabolites capable of being excreted in the urine [40, 389 
45]. When the principal pathway is saturated, the corresponding carboxylic acid conjugates 390 
with glucuronic acid and is excreted in the urine [, 37, 40,  45]. 391 
One of the best studied 2-postion branched carboxylic acid is 2-propyl pentanoic acid (valproic 392 
acid). The toxicokinetic aspects of 2-propyl pentanoic acid have been reviewed [47, 48]. 2-393 
Propyl pentanoic acid is almost entirely metabolised by the liver, so it is not surprising that the 394 
liver is also the dominant target organ of toxicity. The multiple metabolic pathways involved in 395 
2-propyl pentanoic acid biotransformation give rise to more than 50 known metabolites [47]. 396 
Ghodke-Puranik and co-workers [48] estimate that, while 30 - 50% of 2-propyl pentanoic acid 397 
is excreted in the urine as a glucuronide conjugate, 40% goes through mitochondrial β-398 
oxidation and about 10% undergoes cytochrome P450-mediated oxidation. It has been 399 
postulated that the hepatotoxicity of 2-propyl-pentanoic acid results from the mitochondrial β-400 
oxidation of its cytochrome P450 metabolite, 2-propyl-4-pentenoic acid to 2-propyl-(E)-2,4-401 
pentadienoic acid which, in the CoA thioester form, either depletes GSH or produces a putative 402 
inhibitor of β-oxidation enzymes. Pent-4-enoate, 2-propyl-4-pentenoic acid and 2-propyl-(E)-403 
2,4-pentadienoic acid are potent inducers of microvesicular steatosis in rats [49]. However, 404 
since 2-propyl-pentanoic acid failed to induce discernible liver lesions in young rats, even at 405 
near lethal doses of 700 mg/kg/day, Kesterson et al. [49] suggested that β-oxidation inhibition 406 
observed in both valproic acid and unsaturated metabolite-treated rats occurred by different 407 
mechanisms. Specifically, 2-propyl pentanoic acid inhibits transient sequestering of CoA, 408 
while the CoA esters of some metabolites, particularly 2-propyl-4-pentenoic acid, inhibit 409 
specific enzyme(s) in the β-oxidation sequences [49]. 410 
Ghodke-Puranik et al. [48] rationalised the involvement of 2-propyl-4-pentenoic acid. 411 
Specifically, 2-propyl-4-pentenoic acid enters the mitochondria, forms a complex with CoA 412 
ester and subsequent β-oxidation forms the reactive 2-propyl-(E)-2,4-pentadienoic acid-CoA 413 
ester. The latter is the putative cytotoxic metabolite that binds with glutathione to form thiol 414 
conjugates. The reactive metabolite, 2-propyl-(E)-2,4-pentadienoic acid-CoA ester, has the 415 
potential to deplete mitochondrial glutathione pools and form conjugates with CoA, which in 416 
turn inhibits enzymes in the β-oxidation pathway [48]. 417 
In summary, the experimental toxicokinetic data for 2-alkyl-1-alkanols show consistency in 418 
absorption, distribution and metabolic pathways. In contrast, there is less consistency in 419 
excretion. In particular, derivatives with 2-position ethyl and propyl groups are more likely to 420 
be excreted as a glucuronidated metabolite, while 2-position-methylated analogues are more 421 
likely to be oxidized to CO2. The latter are metabolically similar to the less toxic n-alkanols 422 
[2]. The metabolic evidence supporting the idea that some 2-position branched carboxylic acids 423 
are metabolised to thiol reactive metabolites is not considered toxicologically relevant to this 424 
read-across, as repeated-dose toxicity through a reactive mechanism is considered unlikely as 425 
long as the reactive half-life is shorter than the dosing interval (e.g., <8-hr vs. 24-hr) and the 426 
Phase 2 conjugation mechanism is not saturated. 427 
3.4.6 Toxicophore similarity 428 
As shown in Table 6 of the supplemental information, 2-alkyl-1-akanols themselves do not 429 
contain a known toxicophore. However, the carboxylic acid metabolites of the same 2-position 430 
branched isomers (e.g., 2-ethyl-1-hexanol and 2-propyl-1-heptanol) are linked to 431 
developmental toxicity and chronic oral toxicity via the short-chain carboxylic acid pathway 432 
[50]. 433 
3.4.7 Mechanistic plausibility similarity 434 
It is generally accepted that the toxicity of intermediate size 2-alkyl-1-alkanols, like other 435 
saturated alcohols, is the result of narcosis. While there is theoretical evidence for the 436 
membrane as the site of action for anaesthetic-like 2-alkyl-1-alkanols, biochemical, cellular 437 
and physiological evidence is largely restricted to 1-alkanol derivatives [20, 21]. Narcosis, in 438 
the broadest sense, is the non-covalent disruption of hydrophobic interactions within 439 
membranes with a particular volume fraction rather than molar fraction [51]. It is the 440 
accumulation of alcohols in cell membranes which disturbs their function; however, the exact 441 
mechanism is not known yet. There are three competing theories of general anaesthetic action: 442 
1) the lipid solubility-anaesthetic potency correlation (i.e., the Meyer-Overton correlation); 2) 443 
the modern lipid hypothesis and 3) the membrane protein hypothesis. 444 
As shown in Table 7 of Annex I, the alkanols included in the category are associated with the 445 
simple narcosis mechanism of toxicity that is equivalent to depressant anaesthetics. Measured 446 
acute toxicity for 2-alkyl-1-alkanols is consistent with predictions from QSAR models [52, 53] 447 
for the nonpolar narcosis mode of action [54]. 448 
The contributions of functional groups in acute rat oral toxicity have been calculated using 449 
alkanes as the baseline [55]. The toxic contribution of alcohols is -0.108. This situation has not 450 
been observed in acute fish toxicity because the threshold of excess toxicity is too high to 451 
distinguish differences in toxicity. Critical body residues (CBRs) calculated from percentage of 452 
absorption and bioconcentration factors indicate that most of aliphatic alcohols share the same 453 
modes of toxic action between fish and rat. Specifically, fish and rat log (1/CBR) and number 454 
of alcohols are 1.65; 18 and 1.58; 348, respectively [55]. 455 
It should be noted that some 2-alkyl-1-alkanols are associated with development toxicity via 456 
their conversion to the corresponding 2-alkyl-carboxcylic acids. The experimental evidence is 457 
largely confined to 2-ethyl-1-hexanol and the results are mixed. 458 
In rats administrated 1600 mg/kg bw 2-ethyl-1-hexanol by gavage (but not 800 mg/kg bw) on 459 
day 12 of gestation, Ritter et al. [56] reported a statistically significant increase in the number 460 
of teratogenic live fetuses; malformations included hydronephrosis, tail and limb defects. 461 
Maternal toxicity was not reported in this study. 462 
In another study, Ritter et al. [57] proposed that the teratogen di(2-ethylhexyl) phthalate acts by 463 
in vivo hydrolysis to 2-ethyl-1-hexanol, which in turn is metabolised to the definitive teratogen 464 
2-ethyl-1-hexanoic acid. They conducted teratological studies with Wistar rats administering 465 
one of the three agents on day 12 of gestation. Briefly, it was revealed that, on an equimolar 466 
basis, the phthalate derivative was least potent, the alcohol derivative was intermediate, and the 467 
acid derivative was most potent. Similarity in the types of malformation induced by each 468 
derivative suggests a common mechanism of action. In toto, these findings are consistent with 469 
the hypothesis [57]. 470 
Two-ethyl-1-hexanol was evaluated for developmental toxicity in mice [58]. There were no 471 
effects on any gestational parameters upon exposure to dietary 2-ethyl-1-hexanol. Specifically, 472 
the number of corpora lutea, uterine implantation sites (live, dead, resorbed), pre- and post-473 
implantation loss, sex ratio (% males), and live fetal body weight per litter (all foetuses or 474 
separately by sex) were all equivalent across all groups. Moreover, there were no maternal 475 
toxic effects observed at any of the concentrations tested [58]. 476 
Tyl et al. [59] examined the developmental toxicity of 2-ethyl-1-hexanol administered 477 
dermally. In range-finding (8 females / treatment) and definitive investigations (25 females / 478 
treatment), 2-ethyl-1-hexanol was administered by occluded dermal application for 6-hours per 479 
day on gestation days 6 through 15 to pregnant Fischer 344 rats. Treatment levels for range-480 
finding were equivalent to 0, 420, 840, 1680, and 2520 mg/kg bw/d; treatment levels for 481 
definitive experiments were equivalent to 0, 252, 840, and 2520 mg/kg bw/d. Controls included 482 
negative- deionised water, dermal-positive- 2-methoxyethanol and oral reference - valproic 483 
acid. 484 
For 2-ethyl-1-hexanol, the findings are: 1) maternal weight gain was reduced at the two highest 485 
dose levels, 2) maternal liver, kidney, thymus, spleen, adrenal and uterine weights, as well as 486 
gestational and foetal parameters were unaffected by any treatment, and 3) there were no 487 
treatment-related increases in the incidence of individual or pooled external, visceral, and 488 
skeletal malformations or variations. The dermal NOAELs for the maternal toxicity of 2-ethyl-489 
1-hexanol were 252 mg/kg/d based on skin irritation and 840 mg/kg/d based on systemic 490 
toxicity. The developmental toxicity NOAEL was at least 2520 mg/kg/d, with no 491 
teratogenicity. While the Fischer 344 rat is susceptible to known rodent teratogens, such as 2-492 
methoxyethanol by the dermal route and valproic acid by the oral route, in the Fischer 344 rat, 493 
2-ethyl-1-hexanol is not a developmental toxicant by the dermal route at and below treatment 494 
levels which produce maternal toxicity. 495 
Narotsky et al. [60] studied the developmental toxicity and structure-activity relationships of 496 
aliphatic acids in rats. 14 acids were administered by gavage to Sprague-Dawley rats once 497 
daily during organogenesis. Only 2-ethyl hexanoic and 2-propyl hexanoic acid caused effects 498 
similar to valproic acid (i.e., mortality, extra pre-sacral vertebrae, fused ribs, and delayed 499 
parturition) on rat development. Developmental toxicity of α-branched acids is, in part, due to 500 
maternal toxicity resulting in alterations in zinc (Zn) metabolism that affects the developing 501 
conceptus [61]. Developmentally toxic doses of 2-ethyl hexanoic acid, 2-ethyl-1-hexanol and 502 
valproic acid on Zn metabolism were investigated in the pregnant rat. At the higher dose levels 503 
of 2-ethyl-1-hexanoic acid, 2-ethyl-1-hexanol, and at all dosages of valproic acid, the 504 
percentage of 65Zn retained in maternal liver was higher than controls, while that in the 505 
embryos was lower than controls. Two-ethyl-1- hexanoic acid exposed dams fed Zn-containing 506 
diets during gestation exhibited a dose-dependent reduction in teratogenic effects. 507 
Toxicokinetic parameters are important determinants of teratogenic outcome of α-alkyl-508 
substituted carboxylic acids, which helps explain differing potencies of structurally similar 509 
chemicals [62]. Valproic acid (2-propyl-1- pentanoic acid), 2-ethyl-1-hexanoic acid, and 1-510 
octanoic acid are isomeric analogues with markedly different teratogenic potencies. Valproic 511 
acid induces moderate to severe malformations after a single oral administration of 6.25 512 
mmoles/kg on day 12 of rat pregnancy. Twice as much 2-ethyl-1-hexanoic acid (12.5 513 
mmoles/kg) induces a less severe response and 1-octanoic acid is non-teratogenic, even at the 514 
higher dose of 18.75 mmoles/kg [62]. While 1-octanoic acid exhibits poor intestinal 515 
absorption, the peak concentration and duration of exposure to valproic acid and 2-ethyl-1-516 
hexanoic acid were very similar. A fourth agent, 2-methyl-1-hexanoic acid, which is non-517 
teratogenic when administered orally at 14.1 mmoles/kg, exhibits peak concentration and 518 
duration of exposure intermediate to 2-ethyl-1-hexanoic acid and 1-octanoic acid. The 519 
differences in the severity of developmental malformations for the α-alkyl-substituted 520 
derivatives indicated higher intrinsic activity for analogues with C2 and especially, C3 α-alkyl-521 
substituents. 522 
In summary, there is reasonable evidence that some 2-alkyl-1-alkanols via oxidation to their 523 
corresponding acid are probable development toxicants. However, there is no evidence that this 524 
mechanism is related to repeated-dose toxicity. 525 
3.4.8 Other endpoint similarity 526 
In mammals, alkanols, in general, are considered baseline inhalation toxicants which model as 527 
simple narcotics [53].  528 
In fish, alkanols are considered to act via the nonpolar narcosis mode of action, as first reported 529 
by Veith et al. [52]. Alkanols are also represented within the USEPA DSSTox Fathead 530 
Minnow Acute Toxicity (EPAFHM) database. They exhibit toxic potencies not statistically 531 
different from baseline predictions. Because of concerns for aquatic toxicity, a large number of 532 
alcohols, especially saturated ones, have been tested in vitro for cell population growth 533 
inhibition [63]. Structure-activity results from in vivo and in vitro tests are highly consistent 534 
[64]. Briefly, from a structural standpoint, the aquatic toxicity of alkanols is partition-535 
dependent, regardless of endpoint being assessed. 536 
Generally, in vitro, alkanols ascribed to unspecific interactions with biological membranes; 537 
such effects are directly correlated with 1-octanol/water partition coefficients [65]. The 2-538 
alkyl-1-alkanols were screened with a variety of in silico nuclear receptor binding predictions 539 
[66]. Specifically, profilers for nuclear receptor binding were run to identify potential binding 540 
to the following nuclear receptors: PPARs (peroxisome proliferator-activated receptors), AR 541 
(androgen receptor), AHR (aryl hydrocarbon receptor), ER (oestrogen receptor), GR 542 
(glucocorticoid receptor), PR (progesterone receptor), FXR (farnesoid X receptor), LXR (liver 543 
X receptor), PXR (pregnane X receptor), THR (thyroid hormone receptor), VDR (vitamin D 544 
receptor), as well as RAR/RXR (retinoic acid receptor/ retinoid X receptor). The evaluation of 545 
potential binding to the receptors is based on structural fragments and physico-chemical 546 
features that have been identified as essential to bind to these nuclear receptors and induce a 547 
response. No potential receptor binding was predicted. It is worth noting that ToxCast also 548 
tested for all of these receptors, and all assays were negative. 549 
HTS data from US EPA’s ToxCast  [67, 68] are available for a variety of saturated alcohols 550 
[69]. Of the 711 assays available in ToxCast ToxCast, 2-ethyl-1-hexanol has been evaluated in 551 
602 of them and 2-propyl-1-heptanol has been assessed in about 250 assays. The number of 552 
active assays varies, six for 2-ethyl-1-hexanol and four for 2-propyl-1-heptanol. No other 553 
category members have been screened by ToxCast. However, alkanols, in general, are one of 554 
the least promiscuous chemical classes with < 3% of the ToxCast assays show any activity up 555 
to highest concentration tested. None of the active assay are associated with specific bioactivity 556 
[2].  557 
Taken collectively, the findings for other endpoints are not inconsistent with the previously 558 
cited in vivo data and the premise that in oral repeated-dose toxicity, 2-alkyl-1-alkanols act in a 559 
manner similar to depressant anaesthetics. 560 
4. Statement of uncertainty 561 
The categorical assessments of uncertainties along with summary comments are presented in 562 
Tables 4 and 5. 2-Alkyl-1-alkanols are a category with acceptable data uncertainty and robust 563 
strengths-of-evidence for repeated-dose toxicity. Briefly, chemical dissimilarity has no impact 564 
on repeated-dose toxicity. Data uncertainty with the fundamental aspects of toxicokinetics is 565 
low. Regardless of the species of mammal, all such category members are judged to be readily 566 
absorbed orally and to have similar distributions metabolism elimination as glucuronides. Data 567 
uncertainty with the fundamental aspects of toxicodynamics is low, in that category members 568 
exhibit a low-toxic profile with respect to in vivo repeated-dose NOAEL and LOAEL values. 569 
The uncertainty associated with mechanistic relevance and completeness of the read-across is 570 
acceptable. While relevant non-animal data are minimal, the in vivo WoE is high. 2-Alkyl-1-571 
alkanols are thought to be associated with the nonpolar narcosis mechanisms of toxicity. While 572 
well-studied, this molecular mechanism is not well-understood and no adverse outcome 573 
pathway (AOP) is currently available. Moreover, it is unclear if oral repeated-dose toxicity is 574 
related to this mechanism; however, there is no evidence to suggest it is not.  575 
Table 4. Assessment of data uncertainty and strengths-of-evidence associated with the 576 
fundamentals of chemical, transformation/toxicokinetic and toxicodynamic similarity. 577 
Similarity 
Parameter 
Data 
Uncertainty a 
Strength-of-
Evidence b 
Comment 
Substance 
identification, 
structure and 
chemical 
classifications 
Low High All category members are discrete organic substance of 
simple structure. They all have CAS numbers, similar 2D 
structure and belong to the same chemical class and 
subclass. 
    
Physio-chem & 
molecular 
properties 
Empirical: 
Low 
 
High All category members are appropriately similar with respect 
to key physicochemical and molecular properties. Where 
appropriate (e.g., log Kow) changes in values are linked to 
Similarity 
Parameter 
Data 
Uncertainty a 
Strength-of-
Evidence b 
Comment 
Modelled: 
Low 
changes in C-atom number. There is a high degree of 
consistency between measured and model estimated values. 
    
Substituents, 
functional 
groups, & 
extended 
structural 
fragments 
Low High Substituents and functional groups are consistent across all 
category members. There are no extended structural 
fragments. 
    
Transformation/t
oxicokinetics and 
metabolic 
similarity 
Empirical:  
In vivo: Medium 
 
In vitro: none 
 
Simulated: 
Medium 
Medium Based on in vivo data for multiple category members, there 
is evidence for similar toxicokinetics and metabolic 
pathways. It is extremely likely that absorption and 
distribution are consistent within the category. It is likely 
that the metabolic pathways are consistent with the 
category. Comparison of results from empirical studies and 
model predictions indicate similar metabolism among 
category members. Experimental data support the idea that 
2-alkyl-alkanols often undergo oxidation of the alcohol 
group to an acid with degradation to CO2, as well as 
oxidation or hydroxylation of the alkyl chains at various 
positions, and subsequent glucuronidation prior to excretion. 
There is evidence the % of glucuronidation varies within the 
category; higher % of glucuronidation is associated with 2-
position branching > C1. There is also evidence supporting 
the idea that some 2-position branched carboxylic acids are 
metabolised to thiol reactive metabolites which exhibit 
enhanced cellular toxicity. Bioavailability while affected by 
size is not considered a factor in these predictions. 
    
Potential 
metabolic 
products 
Simulated: 
Low 
High Based on in silico metabolic simulations, metabolites from 
hydroxylation and oxidation are predicted to be produced by 
any of the category members. 
    
Toxicophores 
/mechanistic 
alerts 
Medium High Based on in silico profilers, no category member contains 
any established toxicophores related to repeated-dose 
toxicity. 
    
Mechanistic 
plausibility and 
AOP-related 
events 
Medium High Although no AOP is currently available for the 
hypothesized mode of action, many category members have 
been tested for what is generally accepted as 
mechanistically-relevant events (i.e., anaesthesia and 
narcosis). 
    
Other relevant, in 
vivo, in vitro and 
ex vivo endpoints 
Low High Although not directly related to the repeated-dose endpoint, 
many category members have been tested for in vivo acute 
effects in rodents and fish. In addition, many category 
members have been tested in vitro for cellular effects. There 
is general agreement in the trend of the reported LD50, 
LC50 and EC50 values. The primary alkanols (both 
straight-chain and branched) are among the “least 
promiscuous chemical classes” (i.e., only 104 of 4412 assay 
are positive) within ToxCast with no positive assay being 
associated with specific bioactivity. None of the 2-alkyl-1-
Similarity 
Parameter 
Data 
Uncertainty a 
Strength-of-
Evidence b 
Comment 
alkanols reveal any propensity for receptor binding within 
the SEURAT-1 suite of in silico profilers. 
a Uncertainty associated with underlying information/data used in the exercise (empirical, modelled; low, medium, 578 
high) 579 
b Consistency within the information/data used to support the similarity rational and prediction (low, medium, 580 
high) 581 
Table 5. Assessment of uncertainty associated with mechanistic relevance and completeness of 582 
the read-across. 583 
Factor Uncertainty or WoEa Comment 
The problem and 
premise of the read-
across 
Low The endpoint to be read across, oral 90-day repeated-dose 
toxicity, for 2-alkyl-1-alkanols is well-studied and fairly well-
understood mechanistically. The scenario of the read-across 
hinges on metabolism affecting toxic potency but not the mode of 
toxic action (i.e., reversible narcosis). 2-alkyl-1-alkanols, 
themselves, have no obvious chemical reactivity, do not bind to 
any know receptor and exhibit no specific receptor interactions. 
In vivo data read across 
Number of analogues 
in the source set 
Low; 2 of 12 analogues There are two suitable category members (i.e., 2-ethyl-1-hexanol, 
2-propyl-1-heptanol) with high quality in vivo 90-day, oral 
repeated-dose data usable for read-across. 
   
Quality of the in vivo 
apical endpoint data 
read across 
Low Generally, the in vivo data are consistent in regards to qualitative 
description of repeated-dose effects. Lowest observed effects are 
typically haematological or whole body parameters and not 
organ-specific effects. High quality empirical data from accepted 
guidelines for the 90-day repeated-dose endpoint exist for 2-ethyl-
1-hexanol and 2-propyl-1-heptanol and are supported by 90-day 
oral repeated-dose toxicity data for the isotridecano1 mixture.  
   
Severity of the apical 
in vivo hazard 
Low  The consensus is 2-alkyl-1-alkanols have no obvious chemical 
reactivity, do not bind to any known receptor and exhibit no 
specific mode of toxic action. Potency data for the in vivo 90-d 
oral repeated-dose NOAEL is ≈125 mg/kg bw/d based on general 
whole body effects for both sexes. 
Evidence to the biological argument for read-across 
Robustness of 
analogue data set 
Low; numerous 
endpoints reveal the 
same structure-activity 
relationships. 
The available data from acute in vivo and in vitro studies for the 
category members is extensive with several assays being used to 
assess most if not all the analogues, especially the source 
analogues. The tests were judged to be reliable and conducted 
under the appropriate conditions. 
   
Concordance with 
regard to the 
intermediate and 
Low to medium; limited 
by indirect rationale 
(e.g., acute to chronic) of 
Since there is no toxicity pathway for repeated-dose effects for 
this chemical category, there are no true intermediate events. 
There is agreement among the dose-response relationships of the 
apical effects and 
potency data 
mechanistic plausibility. tested category members for relevant in vitro events.  
   
Weight of Evidence High/ medium for 2-
methyl-1-alkanols 
Overall the available information is mainly consistent with the 
stated premise. The structural limitations (i.e., 2-alkyl-1-alkanols) 
of the category strengthen the WoE. While the toxicokinetics data 
is limited, the consistency of the metabolic pathway adds to the 
WoE. Having two well-studied source substances with highly 
similar in vivo 90-day repeated-dose data that are supported by 
similar data for a mixture of C11 to C14 branched alkanols adds 
to the in vivo WoE. Having both 28-day repeated-dose and 
chronic (18-month and 2-year) studies for 2-ethyl-1-hexanol with 
qualitative and quantitative data similar to the 90-day repeated-
dose data adds to the in vivo WoE. Having repeated-dose studies 
for 2-ethyl-1-hexanol with qualitative and quantitative similar 
data in both rat and mouse data adds to the in vivo WoE. The lack 
of in vivo repeated-dose data for 2-methyl derivatives reduced the 
WoE for including these analogues in the category. 
 
a Uncertainty: low, medium, high 584 
 585 
One observed uncertainty is associated with the fact that, while 2-methyl-substituted 586 
derivatives are considered with the domain of the category, there is no in vivo experimental 587 
data supporting their inclusion. However, there is high quality repeated-dose data for 3-methyl-588 
1-butanol (CAS 123-51-3). In a 90-day study with rats, according to OECD Test Guideline 589 
408, 3-methyl-1-butanol was administered in the drinking water in concentrations of 0, ≈80, 590 
≈340 and ≈1250 mg/kg bw/d [70]. A NOAEL of 340 mg/kg bw/d for males and 1250 mg/kg 591 
bw/d for females was reported. 3-Methyl-1-butanol was also tested in a 17-week toxicity study 592 
with Ash/CSE rats [71]. The test substance was administered by gavage to group of 15 rats/sex 593 
at dose levels of 0, 150, 500, or 1000 mg/kg bw/d in corn oil. While a variety of whole body 594 
clinical pathological and histopathological endpoints were examined, the only observed effects 595 
were a statistically significant reduced body weight in males and a non-statistical reduction in 596 
food intake at the highest dose level. A NOAEL of 500 mg/kg bw/d for males and 1000 mg/kg 597 
bw/d for females was reported. In addition, 3-methyl-1-butanol was administered to male and 598 
female Wistar rats (≈2000 mg/kg bw/d) in drinking water for 56 weeks. No treatment-related 599 
effects were observed for whole body, clinical pathology or histopathological endpoints [72]. 600 
In rats, oral administration of 2000 mg 3-methyl-1-butanol /kg bw led to a peak concentration 601 
of 170 mg/l blood at 1 hour [13, 73]; more than 50% of the dose was excreted within 24 hours. 602 
In another study [41], rats were intraperitoneally administered of 250 mg/kg bw four times in 603 
15 minute-intervals. Complete absorption of the substance was observed within 1 hr after final 604 
administration. No test substance was detectable after 4 hrs. Excretion was 2% in urine and 5.6 605 
in expired air. Kamil et al. [15] reported after gavage administration of a dose of 25 mmol per 606 
rabbit (corresponding to ≈ 735 mg/kg bw) of 1-pentanol, 3-methyl-1-butanol, and 2-methyl-1-607 
butanol, approximately 7%, 9%, and 10% of the dose was excreted by the rabbits into urine as 608 
glucuronides, respectively. Furthermore, the urine did not contain aldehydes or ketones. It is 609 
assumed the remaining 90+% of the tested derivative was excreted as CO2. 610 
The collective results for 3-methyl-1-butanol show it is toxicodynamically more similar to 611 
tested n-alkanols (i.e., NOAEL = 1000 mg/kg bw/d) than it is to tested 2-alkyl-1-alkanols (i.e., 612 
NOAEL = 125 mg/kg bw/d). Toxicokinetically, 3-methyl-1-butanol and 2-methyl-1-butanol 613 
are highly similar to n-alkanols, especially 1-pentanol. 614 
5. Conclusions 615 
This is the third in a series of read-across case studies. This specific study is a result of findings 616 
which came to light during evaluations of n-alkanols [2]. In vivo oral repeated-dose exposure to 617 
2-alkyl-1-alkanols gives rise to a set of non-specific symptoms, including clinical symptoms, 618 
haematological values outside the normal range, or whole body effects different from normal. 619 
The category limitation to C5 to C13 analogues assures that the impact of bioavailability on the 620 
toxicokinetic and toxicodynamic profiles is limited. 2-Alkyl-1-alkanols are toxicants which act 621 
via a reversible mode of toxic action. The main route of exposure is oral with rapid 622 
gastrointestinal absorption, distribution via the blood, prompt Phase 2 metabolism and 623 
eliminated in the urine. 624 
Repeated-dose toxicity test results exhibit qualitative consistency between and within species. 625 
While protocols vary, results of oral repeated-dose testing exhibit qualitative consistency 626 
between and within mammals. Typical findings are only mild changes, including decreased 627 
body weight, slightly increased liver weight, as well as clinical chemical and haematological 628 
changes, but typically without concurrent histopathological effects. The 90-day rat oral 629 
repeated-dose NOAEL values for 2-ethyl-1-hexanol and 2-propyl-1-heptanol are particularly 630 
well suited for read-across. Moreover, the predictions are supported by highly similar results 631 
for an isotridecanol mixture. 632 
A NOAEL value of 125 mg/kg bw/d can be read across to fill the data gaps among the 633 
analogues in this category for the purpose of risk assessment. Specifically, the data gaps for 2-634 
propyl-1-pentanol and 2-ethyl-1-octanol are filled with very low uncertainty (very high 635 
confidence) by interpolation from 2-ethyl-1-hexanol and 2-propyl-1-heptanol. The data gaps 636 
for 2-ethyl-1-butanol, 2-ethyl-1-pentanol, 2-ethyl-1-decanol and 2-propyl-1-decanol are filled 637 
with low uncertainty (high confidence) by extrapolation from 2-ethyl-1-hexanol and 2-propyl-638 
1-heptanol. The data gaps for 2-methyl-1-butanol, 2-methyl-1-pentanol, 2-methyl-1-octanol 639 
and 2-methyl-1-undecanol are filled with acceptable uncertainty as worst-case scenarios. The 640 
latter uncertainty results from incomplete knowledge of how a methyl group, rather than an 641 
ethyl or propyl moiety, affects the ratio of excretion in respired CO2, in urine as a conjugate 642 
and in faeces, a as well as repeated-dose toxic potency. 643 
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Table 1. Comparison of Substance Identification, Structure and Chemical Classifications 
ID Name CAS No SMILES 2D Structure Molecular Formula 
1 2-Methyl-1-butanol 137-32-6 CCC(C)CO 
 
C5H12O 
2 2-Methyl-1-pentanol 105-30-6 CCCC(C)CO 
 
C6H14O 
3 2-Ethyl-1-butanol 97-95-0 CCC(CC)CO 
 
C6H14O 
4 2-Ethyl-1-pentanol 27522-11-8 CCCC(CC)CO 
 
C7H16O 
5 2-Ethyl-1-hexanol 104-76-7 CCCCC(CC)CO 
 
C8H18O 
6 2-Propyl-1-pentanol 58175-57-8 CCCC(CCC)CO 
 
C8H18O 
47 
ID Name CAS No SMILES 2D Structure Molecular Formula 
7 2-Methyl-1-octanol 818-81-5 CCCCCCC(C)CO 
 
C9H20O 
8 2-Ethyl-1-octanol 20592-10-3 CCCCCCC(CC)CO 
 
C10H22O 
9 2-Propyl-1-heptanol 10042-59-8 CCCCCC(CCC)CO 
 
C10H22O 
10 2-Methyl-1-undecanol 10522-26-6 CCCCCCCCCC(C)CO 
 
C12H26O 
11 2-Ethyl-1-decanol 21078-65-9 CCCCCCCCC(CC)CO 
 
C12H26O 
12 2-Propyl-1-decanol 60671-35-4 CCCCCCCCC(CCC)CO 
 
C13H28O 
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Table 2: Comparison of Physico-Chemical and Molecular Properties1 
ID Name Molecular Weight1 
Log 
Kow1a 
Vapor 
Pressure 
(Pa, 25 
degC)1b 
Density2 
(g/cm3) 
Melting 
Point 
(deg C)1b 
Water 
Solubility 
(mg/L, 25 
degC) 1c 
Boiling 
Point  
(deg C)1b 
pKa3 
1 2-Methyl-1-butanol 88.15 
1.26 
1.29 (M) 
606 
416 (M) 
0.8±0.1 -61.49 
32200 
29700 (M) 
123.17 
128 (M) 
15.24 
2 2-Methyl-1-pentanol 102.18 1.75 
191 
256 (M) 
0.8±0.1 -49.23 
11950 
6000 (M) 
145.86 
149 (M) 
15.05 
3 2-Ethyl-1-butanol 102.18 1.75 
213 
204 (M) 
0.8±0.1 
-49.23 
<-15 (M) 
11950 
4000 (M) 
145.86 
147 (M) 
15.05 
4 2-Ethyl-1-pentanol 116.21 2.24 66.2 0.8±0.1 -37.23 4089 167.64 15.05 
5 2-Ethyl-1-hexanol 130.23 2.73 
24.6 
18.1 (M) 
0.8±0.1 
-25.50 
-70 (M) 
1379 
880 (M) 
188.52 
184.6 (M) 
15.05 
6 2-Propyl-1-pentanol 130.23 2.73 19.5 0.8±0.1 -25.50 1379 188.52 15.05 
7 2-Methyl-1-octanol 144.26 3.22 5.88 0.8±0.1 -14.04 459.7 208.49 15.09 
8 2-Ethyl-1-octanol 158.29 3.71 1.81 0.8±0.1 -2.83 151.8 227.56 15.09 
9 2-Propylheptan-1-ol 158.29 3.71 3.38 0.8±0.1 -2.83 151.8 
227.56 
217.5 (M) 
15.09 
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ID Name Molecular Weight1 
Log 
Kow1a 
Vapor 
Pressure 
(Pa, 25 
degC)1b 
Density2 
(g/cm3) 
Melting 
Point 
(deg C)1b 
Water 
Solubility 
(mg/L, 25 
degC) 1c 
Boiling 
Point  
(deg C)1b 
pKa3 
10 2-Methyl-1-undecanol 186.34 4.70 0.186 0.8±0.1 18.78 16.18 262.99 15.04 
11 2-Ethyl-1-decanol 186.34 4.70 0.186 0.8±0.1 18.78 16.18 262.99 15.04 
12 2-Propyl-1-decanol 200.37 5.19 0.0615 0.8±0.1 29.19 5.237 279.35 15.06 
M = measured value 
1Values typically derived from EPISuite v4.1, a KOWWIN Program (v1.68), b MPBPWIN v1.43, c at 25 deg C; (mg/L) Kow (WSKOW v1.42); 2 
ACD/Lab Percepta Platform - PhysChem Module (from ChemSpider); 3 Predicted by ACD (Advanced Chemistry Development Inc., Toronto, 
Canada) 
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Table 3: Comparison of Substituents, Functional Groups, and Extended Structural Fragments 
ID Name Key Substituent(s) Functional Group(s) 
Extended 
Fragment(s) Chemical Class Chemical Sub-Class 
1 
2-Methyl-1-butanol -OH -CH3, -CH2-, -CH- – saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
2 2-Methyl-1-pentanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
3 2-Ethyl-1-butanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
4 2-Ethyl-1-pentanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
5 2-Ethyl-1-hexanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
6 
2-Propyl-1-pentanol -OH -CH3, -CH2-, -CH- – saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
7 2-Methyl-1-octanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
8 2-Ethyl-1-octanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
9 2-Propylheptan-1-ol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
10 2-Methyl-1-undecanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
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ID Name Key Substituent(s) Functional Group(s) 
Extended 
Fragment(s) Chemical Class Chemical Sub-Class 
11 2-Ethyl-1-decanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
12 2-Propyl-1-decanol -OH -CH3, -CH2-, -CH- – 
saturated aliphatic 
alcohols 
2-alkyl-1-alkanol 
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Table 4: Comparison of Abiotic Transformation and Toxicokinetics 
 
ID Name Abiotic Transformation 
Toxicokinetics 
Absorption Half-life Elimination 
1 2-Methyl-1-butanol  Efficiently 
following oral 
administrationa 
< 24 hrs 9.6% excreted in the urine as a glucuronides 
within 24 hrsb   
5.6% excreted in air and 2% in urine, remainder 
metabolized, first to the corresponding aldehyde, 
then to the acid c 
Additional oxidation of 2-methyl-1-butanol by 
rat liver microsomes via CYP P450 enzymes, 
and glucuronidationd 
2 2-Methyl-1-pentanol  Efficiently 
following oral 
administration a 
  
3 2-Ethyl-1-butanol  Efficiently 
following oral 
administration a 
 Excreted mainly as a glucuronidese 
4 2-Ethyl-1-pentanol  Efficiently 
following oral 
administration a 
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5 2-Ethyl-1-hexanol atmospheric 
lifetime of 24.6 
hrs 
Efficiently 
following oral 
administrationa 
< 24 hrs 
 
 
 
 
 
 
 
 
 
terminal half-
life 60 hours 
Rapidly excreted in respired CO2 (6-7%), urine 
mainly as glucuronides (80-82%), and faeces (8-
9%); elimination was essentially complete by 28 
hrsf 
After oral administration to rats, within 96 hrs; 
69-75% excreted in urine, about 13-15% in 
faeces, about the same amount exhaled. After 
intravenous administration to rats, within 96 
hours about 74% excreted in urine, about 4% in 
faeces and 23% exhaled. More than 50% 
excreted within 8 hrs.g 
Glucuronide main metabolite (87%) in rabbits b,e 
6 2-Propyl-1-pentanol  Efficiently 
following oral 
administration a 
  
7 2-Methyl-1-octanol  Efficiently 
following oral 
administration a 
  
8 2-Ethyl-1-octanol  Efficiently 
following oral 
administration a 
  
9 2-Propyl-1heptanol  Efficiently 
following oral 
administration a 
  
10 2-Methyl-1-undecanol  Efficiently 
following oral 
administrationa 
  
54 
a Gaillard, D. and Derache, R. 1965. Metabolisation de different alcools, present dans les buissons alcooliques, chez le rat. Trav. Soc. Pharm. Montp., 25: 51-
62; bKamil, I.A., Smith, J.N. and Williams, R.T. 1953a. Studies in detoxication. 46. The metabolism of aliphatic alcohols. The glucuronic acid conjugation of 
acyclic aliphatic alcohols. Biochem. J. 53: 129-136; c Haggard, H.W., Miller, D.P. and Greenberg, L.A. 1945. The amyl alcohols and their ketones: their 
metabolic fates and comparative toxicities. J. Ind. Hyg. Toxicol. 27: 1-14; dIwersen, S. and Schmoldt, A. 1995. ADH independent metabolism of aliphatic 
alcohols: Comparisons of oxidation and glucuronidation. Advan. Forsenic Sci. 4: 19-22; eKamil, I.A., Smith, J.N. and Williams, R.T. 1953b. Studies in 
detoxication. 47. The formation of ester glucuronides of aliphatic acids during the metabolism of 2-ethylbutanol and 2-ethylhexanol. Biochem. J. 53: 137-140; 
fAlbro, P.W. 1975. The metabolism of 2-ethylhexanol in rats. Xenobiotica 5: 625-636, ECHA CHEM A for 2-Ethyl-1-hexanol: 
http://echa.europa.eu/registration-dossier/-/registered-dossier/15194, Joint FAO/WHO expert Committee on Food Additives (JECFA), 1993. Evaluation of 
certain food additives and contaminants. 2-ethyl-1-hexanol. 41st report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Geneva, WHO 
Technical Report Series No. 837; g Deisinger, P.J., Boatman, R.J. and Guest, D. 1993. Pharmacokinetic studies with 2-ethylhexanol in the female Fischer 344 
rat. Toxicologist 13: 179, Deisinger, P.J., Boatman, R.J. and Guest, D. 1994. Metabolism of 2-ethylhexanol administered orally and dermally to the female 
Fischer 344 rat. Xenobiotica 24: 429-440. 
11 2-Ethyl-1-decanol  Efficiently 
following oral 
administrationa 
  
12 2-Propyl-1-decanol  Efficiently 
following oral 
administrationa 
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Table 5: Comparison of Potential Metabolic Products as Predicted in silico 
ID Name 
Liver metabolism simulator Toolbox 
v3.3 MetaPrint2D-React 
software 
SMARTCyp 
version 2.4.2 Meteor Nexus Rat liver S9 Skin metabolism 
1 2-Methyl-1-butanol 
Hydroxylation 
(3) 
Oxidation (1) 
Hydroxylation (3) Hydroxylation 
Oxidation 
Acylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (4) 
Oxidation (1) 
 
2 2-Methyl-1-pentanol 
Hydroxylation 
(2) 
Oxidation (1) 
Hydroxylation (1) Hydroxylation 
Oxidation 
Acylation 
Methylation 
Dealkylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (2) 
Oxidation (1) 
 
3 2-Ethyl-1-butanol 
Hydroxylation 
(2) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dealkylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
 
4 2-Ethyl-1-pentanol 
Hydroxylation 
(4) 
Oxidation (1) 
Hydroxylation (3) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (4) 
Oxidation (1) 
 
5 2-Ethyl-1-hexanol 
Hydroxylation 
(4) 
Oxidation (1) 
Hydroxylation (4) Hydroxylation 
Oxidation 
Acylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (6) 
Oxidation (1) 
 
56 
ID Name 
Liver metabolism simulator Toolbox 
v3.3 MetaPrint2D-React 
software 
SMARTCyp 
version 2.4.2 Meteor Nexus Rat liver S9 Skin metabolism 
6 2-Propyl-1-pentanol 
Hydroxylation 
(2) 
Oxidation (1) 
Hydroxylation (4) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (2) 
Oxidation (1) 
beta-Oxidation of 
Carboxylic Acids (1) 
 
7 2-Methyl-1-octanol 
Hydroxylation 
(3) 
Oxidation (1) 
Hydroxylation (3) Hydroxylation 
Oxidation 
Methylation 
Dealkylation 
Demethylation 
Alkylation 
Acylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (5) 
Oxidation (1) 
8 2-Ethyl-1-octanol 
Hydroxylation 
(4) 
Oxidation (1) 
Hydroxylation (4) Hydroxylation 
Oxidation 
Methylation 
Dealkylation 
Dehydration 
Demethylation 
Alkylation 
Acylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (6) 
Oxidation (1) 
9 2-Propyl-1-heptanol 
Hydroxylation 
(4) 
Oxidation (1) 
Hydroxylation (4) Hydroxylation 
Oxidation 
Acylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (7) 
Oxidation (1) 
 
10 2-Methyl-1-undecanol Hydroxylation Hydroxylation (3) Hydroxylation Possible sites of Hydroxylation (5) 
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ID Name 
Liver metabolism simulator Toolbox 
v3.3 MetaPrint2D-React 
software 
SMARTCyp 
version 2.4.2 Meteor Nexus Rat liver S9 Skin metabolism 
(3) 
Oxidation (1) 
Oxidation 
Acylation 
Methylation 
Alkylation 
Dealkylation 
Demethylation 
metabolism have 
been identified 
Oxidation (1) 
 
11 2-Ethyl-1-decanol 
Hydroxylation 
(4) 
Oxidation (1) 
Hydroxylation (3) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (4) 
Oxidation (1) 
 
12 2-Propyl-1-decanol 
Hydroxylation 
(3) 
Oxidation (1) 
Hydroxylation (1) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Dehydration 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
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Table 6: Comparison of Toxicophores 
ID Name Toxicophores1 
DNA binding by 
OECD1 
Protein binding 
by OECD1 
Nuclear receptor 
binding2 
Liver& 
Mitochondria 
toxicity2 
1 2-Methyl-1-butanol Cramer Class I No alert No alert Inactive No alert 
2 2-Methyl-1-pentanol Cramer Class I No alert No alert Inactive No alert 
3 2-Ethyl-1-butanol Cramer Class I No alert No alert Inactive No alert 
4 2-Ethyl-1-pentanol Cramer Class I No alert No alert Inactive No alert 
5 2-Ethyl-1-hexanol Cramer Class I No alert No alert Inactive No alert 
6 2-Propyl-1-pentanol Cramer Class I No alert No alert Inactive No alert 
7 2-Methyl-1-octanol Cramer Class I No alert No alert Inactive No alert 
8 2-Ethyl-1-octanol Cramer Class I No alert No alert Inactive No alert 
9 2-Propyl-1-heptanol Cramer Class I No alert No alert Inactive No alert 
10 2-Methyl-1-undecanol Cramer Class I No alert No alert Inactive No alert 
11 2-Ethyl-1-decanol Cramer Class I No alert No alert Inactive No alert 
12 2-Propyl-1-decanol Cramer Class I No alert No alert Inactive No alert 
1 OECD QSAR Toolbox 3.3; 2 COSMOS profilers available via COSMOS space: http://cosmosspace.cosmostox.eu 
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Table 7: Comparison of Mechanistic Plausibility and AOP-Related Event Data 
ID Name Mechanistic Plausibility 
Adverse 
Outcome 
Pathway or 
Mode of Toxic 
Action: 
Molecular 
Initiating 
Event: 
Key Event 1 
etc. 
Key Event 
Relationship 1 
etc. 
Other 
Mechanistically-
Relevant Events 
1 
2-Methyl-1-butanol 
 Narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
2 
2-Methyl-1-
pentanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
3 
2-Ethyl-1-butanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
4 
2-Ethyl-1-pentanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
5 
2-Ethyl-1-hexanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
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ID Name Mechanistic Plausibility 
Adverse 
Outcome 
Pathway or 
Mode of Toxic 
Action: 
Molecular 
Initiating 
Event: 
Key Event 1 
etc. 
Key Event 
Relationship 1 
etc. 
Other 
Mechanistically-
Relevant Events 
6 
2-Propyl-1-pentanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
7 
2-Methyl-1-octanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
8 
2-Ethyl-1-octanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
9 
2-Propyl-1-heptanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
10 
2-Methyl-1-
undecanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
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ID Name Mechanistic Plausibility 
Adverse 
Outcome 
Pathway or 
Mode of Toxic 
Action: 
Molecular 
Initiating 
Event: 
Key Event 1 
etc. 
Key Event 
Relationship 1 
etc. 
Other 
Mechanistically-
Relevant Events 
11 
2-Ethyl-1-decanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
   
12 
2-Propyl-1-decanol 
 narcosis - 
depressant 
anesthesia 
Unspecific 
interactions with 
biological 
membranes 
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Table 8: Comparison of Toxicologically Relevant in vivo, in vitro and ex vivo Data 
Name 
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Endpoint: NOAEL 
(Repeat dose toxicity) 
     25-1000 
(mg/kg/d) 
   30-150 
(mg/kg/d) 
    
     [2, 3, 5, 22]    [4, 21]     
Endpoint: NOEL 
(Repeat dose toxicity) 
>6400 (mg/m3)               
[1]              
Endpoint: NOAEL 
(short-term repeated 
dose study) 
    100-200  
 (mg/kg bw/d)  
[5, 23-26] 
       
Endpoint: LOAEL 
(Repeat dose toxicity) 
    1525 (mg/kg/d) 
[5] 
   150-600 
(mg/kg/d) 
[4] 
   
 
Endpoint: NOAEC 
(Repeat dose toxicity) 
     120-638.4 
(mg/kg/d) 
         
     [6]          
Endpoint: NOAEL 
(Reproductive 
toxicity) 
     130-2520 
(mg/kg/d) 
   50 (mg/kg/d)     
     [6]    [7]     
Endpoint: NOAEL ( 
Teratogenicity) 
     191-650 
(mg/kg/d) 
   158-600 
(mg/kg/d) 
    
     [6]    [7]     
Endpoint: HNEL 
(Carcinogenic/ 
Genotoxicity)  
     50-200 
(mg/kg/d) 
         
     [8]          
Endpoint: LEL      150-750 (mg/kg/d) 
         
63 
(Carcinogenic/ 
Genotoxicity)  
     [8]          
Endpoint:  LC50  
(Acute  toxicity) 
     0.89- 5.3 
(mg/Lair) 
   >0.13(mg/L 
air) 
    
     [6]    [7]     
               
Endpoint: LD50  
(Acute  toxicity) 
1900-5000 
(mg/kg) 12.53-
16.6 (mg/Lair)   
3.54 (mL/kg) 
   3730 (mg/kg)    5100-5400 
(mg/kg) 
    
[1, 9]    [6, 10, 11]    [7]     
Endpoint: oral LD50 
(mg/kg)   
(Acute toxicity) 
4010  
mg/kg bw [17] 
 1850  
mg/kg bw 
[18] 
 2000-3730 
mg/kg bw 
 [5, 19-20] 
   5400 mg/kg 
bw [21] 
   
Endpoint: LDLo  
(Acute  toxicity) 
1900- 2448 
(mg/kg) 
              
[1, 12]               
Endpoint: 
Genotoxicity (AMES, 
Chromosomal 
abrration, gene 
mutation) 
2 x Negative    9 x Negative    5 x Negative     
[13-16]    [5]    [4]     
T
oxcast [27] 
ATG_ERa_TRA
NS  
   11.9    
  
  
ATG_ERa_TRA
NS_perc 
    5.77        
ATG_PXRE_CI
S 
    31.1        
ATG_PXRE_CI
S_perc 
    31.1        
OT_ERa_EREL
UC_AG_1440 
        3.14    
Tox21_AR_BL
A_Agonist_ch1 
        0.00219    
64 
Tox21_ELG1_L
UC_Agonist_via
bility 
 
   
 
   
54.9  
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